Sangamo Therapeutics, Inc.

SGMO

US8006771062

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-12 pm EDT			5-day change	1st Jan Change
0.4548 ^USD	+3.74%		+41.02%	-16.29%

May. 14	Transcript : Sangamo Therapeutics, Inc. Presents at 2024 RBC Capital Markets Global Healthcare Conference, May-14-2024 08:30 AM
May. 09	Transcript : Sangamo Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024

Sangamo Therapeutics, Inc. Appoints D. Mark Mcclung as Chief Operating Officer

November 04, 2021 at 09:06 am EDT

Sangamo Therapeutics, Inc. appointed D. Mark McClung as Chief Operating Officer.

Latest news about Sangamo Therapeutics, Inc.

Transcript : Sangamo Therapeutics, Inc. Presents at 2024 RBC Capital Markets Global Healthcare Conference, May-14-2024 08:30 AM	May. 14
Transcript : Sangamo Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024	May. 09
Earnings Flash (SGMO) SANGAMO THERAPEUTICS Reports Q1 Revenue $481,000	May. 09	MT
Sangamo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
Sangamo Therapeutics, Inc. Reports Impairment Charges for the First Quarter Ended March 31, 2024	May. 09	CI
Sangamo Therapeutics Prices $24 Million Registered Direct Offering	Mar. 22	MT
Sangamo Therapeutics Pushes Neurology Programs Toward Clinical Development, Wedbush Says	Mar. 14	MT
Transcript : Sangamo Therapeutics, Inc., Q4 2023 Earnings Call, Mar 13, 2024	Mar. 13
Sangamo Therapeutics, Inc. Reports Impairment Results for the Fourth Quarter Ended December 31, 2023	Mar. 13	CI
Sangamo Therapeutics Announces Data from Novel Proprietary Neurotropic Aav Capsid Demonstrating Industry-Leading Blood-Brain Barrier Penetration and Brain Transduction in Nhps	Mar. 13	CI
Sangamo Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 13	CI
Sangamo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 13	CI
Sangamo Therapeutics Says Early Phase 1/2 Data Shows 'Durable' Safety, Efficacy of Fabry Disease Drug Candidate	Feb. 06	MT
Sangamo Therapeutics, Inc. Announces Updated Preliminary Data from the Phase 1/2 STAAR Clinical Study Evaluating Isaralgagene Civaparvovec, or ST-920	Feb. 04	CI
Vaxcyte Names Chief People Officer	Jan. 16	MT
Sangamo Therapeutics, Inc.(NasdaqGS:SGMO) dropped from NASDAQ Biotechnology Index	Dec. 15	CI
Sangamo Therapeutics, Inc Announces Pivotal Readout in the Middle of 2024 for the Phase 3 Affine Trial	Dec. 13	CI
North American Morning Briefing : Stock Futures -2-	Nov. 08	DJ
Truist Securities Downgrades Sangamo Therapeutics to Hold From Buy	Nov. 07	MT
North American Morning Briefing : Higher Bond -2-	Nov. 07	DJ
HC Wainwright Cuts Price Target on Sangamo Therapeutics to $3 From $5, Maintains Buy Rating	Nov. 06	MT
Wells Fargo Downgrades Sangamo Therapeutics to Equal-Weight From Overweight, Price Target is $1	Nov. 06	MT
North American Morning Briefing : Stocks Look to -2-	Nov. 06	DJ
Wedbush Lowers Sangamo Therapeutics' PT to $2 From $10 as Result of Valuing Potential Royalty From ST-920 Sales, Keeps Outperform Rating	Nov. 03	MT
RBC Downgrades Sangamo Therapeutics to Sector Perform From Outperform, Cuts Price Target to $2 From $6, Cites 'Cash Preservation Mode,' Keeps Speculative Risk	Nov. 03	MT

Chart Sangamo Therapeutics, Inc.

Duration

Period

More charts

Sangamo Therapeutics, Inc. is a genomic medicines company that is developing medicines for neurological diseases. The Company's neurology preclinical development is focused on two areas: development of epigenetic regulation therapies to treat serious neurological diseases, and development of novel engineered adeno-associated virus (AAV) capsids to deliver its therapies to the intended neurological targets. The Company's zinc finger epigenetic regulators are ideally suited to potentially address neurological disorders and its capsid discovery platform is expanding delivery beyond intrathecal delivery capsids, including in the central nervous system. Its clinical-stage product candidates are Isaralgagene civaparvovec, also known as ST-920, its wholly-owned gene therapy product candidate for the treatment of Fabry disease, and TX200, its wholly-owned CAR-Treg cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation.

Sector

Biotechnology & Medical Research

Calendar

2024-08-06 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Sangamo Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.4548 USD

Average target price

3.8 USD

Spread / Average Target

+735.53%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SANGAMO THERAPEUTICS, INC.	-16.29%	94.38M
VERTEX PHARMACEUTICALS INCORPORATED	+20.12%	126B
REGENERON PHARMACEUTICALS, INC.	+25.25%	119B
ARGENX SE	+25.56%	27.95B
BIONTECH SE	-19.51%	20.5B
GENMAB A/S	-14.36%	17.12B
BEIGENE, LTD.	-15.63%	16.1B
WUXI APPTEC CO., LTD.	-46.67%	14.97B
NEUROCRINE BIOSCIENCES, INC.	+11.89%	14.84B
SAREPTA THERAPEUTICS, INC.	+57.74%	14.38B

Bio Therapeutic Drugs